Author: CannabisNewsWire (CNW)

About CannabisNewsWire CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CannabisNewsWire.com Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

420 with CNW — Study Shows Users of Medical Cannabis Register Improvements in Depression, Anxiety and Pain

A recent study in the “PLoS ONE” journal found that more than 2,300 individuals with persistent health issues experienced improved well-being and reduced fatigue within the first three months of using medicinal cannabis. The study was centered on the responses obtained from eligible Australian patients who participated in the QUEST Initiative.

The participants’ age spectrum spanned from 18 to 97 years of age, with an average age of 51. Among the participants, 62.8% were women while 37.2% were men. The majority of participants reported experiencing chronic pain (69%), followed by insomnia (23%), anxiety (22%), and a combination of anxiety and depression (11%).

Before starting cannabis treatment, the participants were tasked with completing initial surveys concerning their health-related quality of life (HRQL), pain levels, sleep patterns, fatigue levels, and depression and anxiety symptoms. Subsequent follow-up surveys were administered at the two-week mark and then on a monthly basis for three months.

All participants were prescribed Little Green Pharma’s medical marijuana oil, comprising CBD and THC dissolved in MCT oil. This product was available in four different formulations featuring varying THC-to-CBD ratios: 1:20, 10:10, 20:5 and CBD only.

When compared to initial baselines, patients who faithfully adhered to the three-month treatment regimen reported notable enhancements in their overall health-related quality of life. In contrast, individuals who only completed the first follow-up assessment demonstrated less progress compared to those who persisted with the treatment.

With regard to pain management, the study revealed that participants, on the whole, exhibited improvements in pain-related metrics. The magnitude of improvement, however, was more pronounced among those diagnosed with chronic pain conditions compared to those not receiving pain-focused treatment.

Sleep patterns did not witness any significant amelioration among the respondents; nevertheless, a reduction in fatigue levels was noted, signifying clinically meaningful improvements.

Regarding depression, the research disclosed that while scores shifted from moderate to mild severity, they failed to reach the five-point threshold indicative of clinically meaningful improvement. However, substantial improvement was observed among individuals diagnosed with specific conditions.

Anxiety scores displayed analogous trends, revealing significant improvements over time but falling short of reaching the expected threshold, except in cases where participants were diagnosed with anxiety conditions.

Throughout the three-month period, a total of 127 participants formally withdrew from the study, citing various reasons for doing so. These included perceived ineffectiveness of the treatment, alterations in treatment plans, unwanted side effects and the perceived high cost of cannabis products. However, the majority reported at least some degree of relief from their ailments.

Despite the generally favorable outcomes, the researchers acknowledged that certain reported improvements might be attributed to the placebo effect.

Looking ahead, the study intends to continue tracking patients for a full 12 months to assess the sustainability of the observed improvements in patient-reported outcomes. Additionally, further subgroup analyses will be conducted to ascertain whether patients with specific conditions experience superior outcomes when evaluated using condition-specific questionnaires.

This study pointing to the beneficial effects of medical marijuana could be good news to companies that are looking to popularize their medicinal cannabis products in different markets around the world, such as TerrAscend Corp. (TSX: TSND) (OTCQX: TSNDF).

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 Expo 2023: Celebrating the Cannabis Culture

Cannabis enthusiasts, investors, decision-makers, and business owners, are invited to attend the 420 Expo 2023 to be held in New Jersey Expo Center, Edison, NJ from September 29 – October 1, 2023. The electrifying event is set to blaze the ever-evolving cannabis landscape, including medical experts discussing the therapeutic potential of cannabis and professionals sharing their success stories.

420 Expo 2023 is a one-of-a-kind gathering that celebrates the world of cannabis culture, from its insightful medical applications to its important role in mainstream culture. Featuring the legendary Cheech Marin as a special guest host, the dynamic cannabis convergence promises to deliver the creative side of cannabis culture. The iconic figure will be meeting fans for photos and autographs along with about a dozen other marijuana-relevant celebrities, infusing the convention with an exclusive blend of pop culture.

Innovating the Cannabis Community

The 420 Expo 2023 will serve as a knowledge goldmine with some of the most prominent experts in the cannabis industry delivering engaging talks and panel discussions. Hosted at the New Jersey Expo Center, the convention is renowned for its advanced cannabis policies. The event will feature live performances and cannabis-inspired art from entertainers who’ve made cannabis an integral part of their culture. As a dynamic union of everything cannabis, the expo promises to promote innovation, education, community and healing.

The expo aims to leave participants inspired, informed, and equipped with a deeper understanding of the cannabis landscape. It features dedicated outdoor smoking areas with food trucks, over 100 vendors, celebrity appearances, live music, stage performances, panel discussions, educational seminars, a full VIP program, and nightly VIP after-parties. Interested participants should register for the 420 Expo 2023 now. Don’t miss out on the largest cannabis event of the year.

To learn more, please visit https://cnw.fm/jGy7u.

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — California Senate OKs Marijuana Cafes Bill

The California senate has passed a marijuana cafe bill that would give dispensaries permission to provide noncannabis drinks and foods to customers who have approval from local authorities. State senators passed Assemblymember Matt Haney’s Bill AB 374 in a 33 to 3 vote before sending it back to the assembly for a concurrence vote thanks to slight amendments made in a Senate committee.

If the assembly votes in favor of the amended cannabis cafe bill, it could head to California Governor Gavin Newsom’s desk for his signature.

The marijuana consumption cafe bill would grant local governments the authority to allow cannabis consumption lounges within their jurisdictions to sell noncannabis-infused soft drinks and foods. It would also prohibit the sale of alcoholic beverages and the consumption of tobacco at these facilities. Furthermore, the measure would also allow “live music and other performances” and the sale of tickets to these performance events in cannabis consumption lounges.

Microbusinesses and retailers where marijuana consumption is allowed would only be permitted to sell freshly prepared drinks and foods to customers. However, only retailers would be allowed to offer prepacked food.

These regulations are in line with policies adopted by the California Department of Cannabis Control (DCC) in late 2022.

Assemblymembers also revised the bill to make it clear that hemp-based drinks and foods did not qualify as noncannabis products that could be sold at cannabis consumption lounges. The measure was also revised to include stipulations requiring that cannabis products and noncannabis products be stored and displayed in separate locations.

Although some businesses in California have found ways to circumvent laws banning on-site consumption establishments from providing food to guests, these establishments currently operate in a grey area.

Cannabis consumption sites have been controversial since they were first introduced. Most states with legal cannabis programs have banned public consumption and require that users only consume cannabis in their private residences. This means that tourists who travel to states with recreational cannabis programs often have no way to legally consume the cannabis they buy from licensed dispensaries, potentially depriving states of billions of dollars in cannabis tourism revenue.

Most of the consumption lounges in California were located in Oakland and San Francisco by the end of last year. However, municipalities in Central Valley and Southern California are giving consumption lounges the green light. With new lounges opening in Coalinga, Central Valley, Desert Hot Springs and Palm Springs in Riverside County along with Port Hueneme in Ventura County and National City in San Diego County, the number of consumption lounges in California is expected to grow by two to three times over the next couple of years.

As different jurisdictions move to create enabling laws for marijuana consumption lounges, entities such as Tilray Brands Inc. (NASDAQ: TLRY) (TSX: TLRY) are likely to see higher demand for their products as consumers have public locations within which they can consume the marijuana products they buy.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Israel, Australia Ranked as Top Importers of Canadian Medical Marijuana

New data from Health Canada has revealed that Australia and Israel were the top buyers of Canada’s medical marijuana exports in 2022. Figures shared through MJBizDaily show that the two nations were the largest markets for Canadian medical cannabis importers amid a surge in cannabis exports from Canada.

Medical cannabis flower exports from the North American nation totaled around 132,200 pounds for fiscal year April 2022 through March 2023 and went up by 48% from the previous fiscal year’s roughly 90,000 pounds. Close to 80% of medical marijuana flower exports from Canada (104,000 pounds) went to Australia and Israel and 16% (21,000 pounds) went to Germany.

Canada has exported 277,000 pounds (126,025 kilograms) of medical marijuana flower for commercial and scientific use since 2017, MJBizDaily reports. The value of Canada’s medical marijuana exports in 2022 also increased by 50% from the fiscal year 2021–2022 to around $118 million. However, while players in the cannabis industry are likely pleased with the increased international demand for their cannabis flower, relying on three nations for the majority of exports puts the Canadian medical marijuana export segment at significant risk.

According to Miguel Martin, the CEO of Edmonton, Canada, cannabis producer Aurora Cannabis, investing in medical marijuana flower exports is a “long-term play.” He noted that export margins are 2.5 times higher than margins in the local recreational marijuana market and are “not declining.”

Although Australia and Israel were both major importers of Canadian medical cannabis flower, Australia imported most of Canada’s cannabis extracts in 2022. Of the 2,388 gallons of medical cannabis extract Canada exported last year, 2,217 gallons went to Australia followed by the Cayman Islands at 845 gallons, and Brazil, Barbados and South Africa at 35 gallons, 27 gallons and 23 gallons respectively.

Cannabis producers in Canada have become increasingly focused on the international market due to higher margins compared to the Canadian market, which is plagued with issues such as oversaturation and oversupply. Additionally, excise taxes levied by Canadian authorities on cannabis products reduce margins for cannabis producers in local markets and incentivize them to seek business partnerships with buyers in other nations.

Thanks to significantly reduced competition in foreign markets such as Israel and Australia, Canadian medical cannabis exporters don’t have to worry about sharing their market with an increasing number of sellers. However, nations such as Denmark and Columbia are becoming increasingly relevant in the global cannabis trade and may soon begin eating into Canada’s market share. Companies such as SNDL Inc. (NASDAQ: SNDL) therefore have to step up their innovativeness even more in order to stay ahead of the competition.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

Lexaria Bioscience Corp. (NASDAQ: LEXX) is On Track for IND Application with the FDA for its Planned U.S. Phase 1b Hypertension Clinical Trial

Lexaria’s IND application for its U.S. Phase 1b Hypertension Clinical Study, HYPER-H23-1, remains on track despite setbacks
Work mostly under Lexaria’s control was completed earlier this year, while work that is outside its control remains delayed
Regardless, Lexaria continues to make progress, even as it looks to take advantage of the growing global cardiovascular drugs market, which is projected to post a CAGR of 3.1% between 2021 and 2026
Chris Bunka, Lexaria’s CEO, has lauded the company’s exceptional discovery, which demonstrates the ability of the patented DehydraTECH-processed CBD to lower blood pressure in the patient population

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, remains on track for its upcoming submission of an Investigational New Drug (“IND”) application for its planned U.S. Phase 1b Hypertension Clinical Trial, dubbed HYPER-H23-1. The study, entitled “A Phase 1b Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Pharmacodynamics of DehydraTECH-CBD in Subjects with Stage 1 or Stage 2 Hypertension,” looks to evaluate the safety and tolerability of Lexaria’s patented DehydraTECH(TM)-processed CBD in hypertensive patients (https://cnw.fm/8q5JV).

This study builds on five previous human clinical studies conducted from 2018 to 2022, which will be integral to the successful filing and review of the planned IND submission. Most notably, the studies, which involved 134 healthy and hypertensive persons, evidenced significant reductions in resting blood pressure over both acute and multi-week dosing regimens. In addition, the studies also showed zero serious adverse events, evidencing DehydraTECH-CBD’s potential to have pronounced clinical benefits relative to available anti-hypertensive therapeutics.

Work that is mainly under Lexaria’s control was completed earlier this year. This included batch manufacturing of DehydraTECH-CBD and placebo materials necessary for the application. However, work outside of Lexaria’s control remains delayed. This includes the provision of required documentation by a materials supplier and stability testing of the material. As such, Lexaria cannot yet submit the IND package to the FDA until the delays have been addressed, although progress is still being made.

In 2021, the global cardiovascular drugs market was estimated at $146.51 billion. By 2026, the market is expected to be valued at $173.48 billion, posting a CAGR of 3.1% (https://cnw.fm/ry230). Lexaria looks to capitalize on this growth while carving a decent market share. The IND application with the FDA will be integral to the company realizing this goal and bringing relief to the many people living with cardiovascular conditions.

“That we were able to lower blood pressure in our patient population over multiple weeks using DehydraTECH-CBD is an exceptional discovery, given that previous studies by others using other oral CBD formulations have failed to evidence this sustained benefit,” noted Chris Bunka, Lexaria’s CEO (https://cnw.fm/f76N9).

So far, Lexaria is aware of only a handful of other published research studies that have investigated whether a sustained decrease in resting blood pressure is possible following multiple weeks of oral CBD dosing. However, it notes that none have succeeded in achieving this, proving DehydraTECH-CBD’s superior power to reduce blood pressure over other oral CBD formulations.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Data Shows Border Sales Boosting Retailers’ Earnings in US

Marijuana sales crossing state lines have proven to be a lucrative source of revenue for retailers in the United States, and recent data suggests that a similar trend is emerging along international borders, particularly with Mexico. Insights gathered from various sources, including LeafLink, quarterly reports, state agencies and interviews with marijuana companies, support this observation.

LeafLink’s analysis of numerous ZIP codes found that when new recreational marijuana markets open, retailers near state borders tend to increase their inventory orders significantly compared to those located further inland. Over the past three years, wholesale cannabis product purchases by border stores surged by 140% after the introduction of recreational sales. In contrast, retailers situated in more interior regions increased their purchases by only 80%.

Several factors contribute to these trends, with neighboring state marijuana regulations playing a significant role. For example, Illinois retailers near Wisconsin continue to attract Wisconsinites even after four years of recreational sales in Illinois because marijuana possession remains illegal in Wisconsin.

Additionally, varying retail sales taxes play a part. Operators in the St. Louis area are witnessing an influx of shoppers from southern Illinois, where marijuana taxes are triple the rate of Missouri’s.

Missouri’s recent launch of adult-use sales has created a ripple effect in the Midwest, as it borders eight states, with Illinois being the sole state offering recreational marijuana sales. Missouri’s low 6% retail tax on recreational marijuana purchases attracts Illinois consumers, resulting in significant foot traffic across the Mississippi River.

The impact extends to the wholesale market, with wholesale purchases per store in the Kansas City, Missouri, market increasing by 406% after the launch of recreational sales, according to LeafLink data. Similarly, in the St. Louis market, wholesale purchases per store increased by nearly 57%.

In Maryland, which recently entered the recreational cannabis market, retailers along the state’s borders are experiencing increased demand, with some doubling their orders to meet customer needs. Wholesale product orders increased by 115% in Elkton, near the Delaware border, while in the Germantown/Rockville area, monthly wholesale purchases rose by about 42% since recreational sales began.

Across the U.S.-Mexico border, commercial ties run deep, with residents often crossing freely between Sunland Park, El Paso and Juarez for various purposes, including shopping for regulated marijuana. Other border communities, including Hobbs and Clovis, are also witnessing strong sales, indicating that Texans and some Mexicans are crossing the border to purchase marijuana from New Mexico retailers.

It is highly likely that as cannabis retailers along borders see increased sales, other ancillary businesses such as Innovative Industrial Properties Inc. (NYSE: IIPR) may also be benefiting from this boom as demand for their products and services rises.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Maryland Sells Record-Setting $92M Cannabis During Second Month of Recreational Marijuana Sales

Maryland’s marijuana market achieved another milestone last month, with retailers notching almost $92 million in sales, marking the state’s second month of recreational cannabis sales. This surge represents a significant leap from July’s $87 million, illustrating the transformative impact of expanding cannabis access beyond the medical sector, more than doubling prior sales figures.

Data recently released by the state’s cannabis regulator, MCA, indicates that legal dispensaries tallied sales exceeding $91.7 million. Smokeable flower sales were in the lead at $55.1 million, followed by concentrates at $24.7 million, while infused edibles and nonedibles contributed $6.2 million and $5.2 million, respectively. Trim or shake products brought in $512,991, with marijuana plants contributing $9,588.

July saw a surge in marijuana sales, coinciding with the enactment of a law allowing the state’s medical stores to serve all adults aged 21 years and older. The opening weekend of this transition resulted in an impressive $10 million in cannabis product sales.

Multistate operators (MSOs) have emerged as prominent players in Maryland’s cannabis market, with companies such as Ascend, GTI, Verona and Curaleaf reporting the highest sales figures for the past month.

Later this year, Maryland officials will start taking applications for social-justice cannabis company licenses. The Social Equity Verification Portal, which MCA unveiled last week, will start letting potential applicants determine whether they qualify for the new licenses this week. Equity candidates will be the only ones eligible for the initial round of new cannabis grower, processor, and store licenses.

Maryland levies a 9% sales tax on cannabis for adult use; medical sales are excluded. This indicates that the policy change has already resulted in a few million dollars entering the state’s coffers.

A prohibitionist organization, Smart Approaches to Marijuana, has criticized the state’s management of tax collection. The group alleges that the state’s Office of the Comptroller was actively working to defend banks that were breaking the law.

The accusation was made following the publication of remarks made by Rob Scheerer, director of the Revenue Administration Division of the Maryland Office of the Comptroller, during a Maryland Association of Counties conference last month. Scheerer stated that to safeguard banks, the term “cannabis” could not be used on tax returns, instead employing the term “a sale subject to the 9% rate under SB516 of 2023.”

Both the Office of the Comptroller and Wells Fargo, its banking partner, have asserted that they adhere to the law.

The surging sales in Maryland suggest that the companies operating within that market could see the kind of success that enterprises such as Curaleaf Holdings Inc. (CSE: CURA) (OTCQX: CURLF) have enjoyed in the markets in which they operate.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Key Senate Committee Chair Promises to Advance Cannabis Banking Bill

The chairman of a key Senate committee has revealed that he discussed the possibility of advancing bipartisan cannabis banking legislation within the next six weeks with Senate Majority Leader Chuck Schumer. During a recent interview with Punchbowl News, Senate Banking Committee chair Sherrod Brown said that he talked to Schumer about moving the Secure and Fair Enforcement (SAFE) Banking Act alongside several other major bills within the next one and a half months.

Cannabis banking has been a contentious issue since states began legalizing medical and recreational cannabis in the United States nearly two decades ago. Although dozens of states now have legal cannabis programs, federal law still classifies marijuana as a Schedule I drug with no medical application. As a result of federal prohibition, licensed cannabis operators find it nigh impossible to access critical financial services such as banking, cashless payments, capital and financial aid.

This forces cannabis businesses to operate on a mostly cash-only basis and puts these businesses at significant risk of violent robberies, something that has been occurring in recent months with increasing frequency. The SAFE Banking Act was introduced to address the lack of access to financial services in America’s multibillion-dollar cannabis industry.

In a recent floor speech and in a letter to fellow lawmakers, Schumer said providing the cannabis industry with access to banking is a priority. He noted that although “making progress on cannabis” via banking legislation was a legislative priority, the legislation wouldn’t progress on the Senate floor without bipartisan support on cannabis reform and related issues, including capping insulin prices and competing with China on the global scale. Additionally, spending legislation will take up a lot of the Senators’ time in the next few weeks, likely reducing the time they have to discuss cannabis banking.

One key section of the SAFE Banking Act (Section 10) has also been subject to intense debate among lawmakers in recent months and even prevented the measure from passing during the summer legislative session.

In late July, Schumer said lawmakers having bipartisan negotiations over the SAFE Banking Act were “making good progress.” The Senate Majority leader reportedly told a lobbyist at the time that Senate lawmakers were working on cannabis banking. He had previously stated that he wished to address marijuana banking reform during the summer session but constant debate over sections of the cannabis banking bill have kept the measure from advancing until the end of the session.

The marijuana industry and its leading entities such as Green Thumb Industries Inc. (CSE: GTII) (OTCQX: GTBIF) have heard such promises before and are unlikely to get too excited by these new pronouncements until actual banking reform is enacted at the federal level.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — NORML Says Rescheduling Cannabis Not Enough

Almost a year after the President Biden administration initiated the process urging the Department of Health and Human Services (HSS) to swiftly evaluate the federal scheduling of marijuana, HHS Secretary Xavier Becerra has affirmed the agency’s recommendation to reclassify cannabis from a Schedule I drug to a lower classification. Although the specific details of the HHS recommendation remain undisclosed, recent Bloomberg News reports indicate that the department advocates moving cannabis to Schedule III within the federal Controlled Substances Act (CSA).

This proposed alteration has garnered praise from certain quarters, particularly within the commercial marijuana industry, as a significant stride forward. Conversely, entities such as NORML have adopted a more measured stance. NORML asserts that there are three key reasons why cannabis ought to be descheduled rather than rescheduled.

First, moving cannabis to a lower schedule under the CSA continues to exaggerate the plant’s purported safety risks in comparison to other controlled drugs, including benzodiazepines (classified as Schedule IV), ketamine and anabolic steroids (presently under Schedule III), or alcohol, which remains unscheduled.

Secondly, moving marijuana to Schedule III deviates from cultural and public consensus. Americans do not wish to equate cannabis with heroin, as it currently stands, but they also oppose its association with Schedule III substances such as ketamine, which can only be legally possessed with a physician’s prescription.

Most crucially, this proposed alteration doesn’t do much to reconcile the growing disparity between federal and state-legal cannabis legislation. If the administration reclassifies cannabis as a Schedule III substance, all state laws currently in conflict with federal-level legislation will persist in their conflict.

Conversely, NORML has consistently advocated for the complete descheduling of cannabis, effectively removing it from the CSA. This approach would empower states, rather than the federal government, to regulate cannabis according to their preferences without violating federal legislation. In a NORML blog post addressing this matter, Paul Armentano, NORML deputy director, expressed his ongoing efforts in promoting NORML’s descheduling initiative to numerous mainstream media channels, including PBS, UPI, the Washington Post and the Associated Press, thereby reaching millions of individuals.

During one of his appearances on CNN, Armentano stated that alcohol and tobacco are conspicuously absent from the CSA, yet they are widely acknowledged to pose significantly greater health hazards than cannabis. He thus argued that cannabis should receive the same treatment when it comes to federal scheduling.

NORML positions itself as a grassroots organization championing freedom and civil liberties while advocating for the interests of responsible cannabis consumers and remaining committed to advancing the case for sensible marijuana policies, including descheduling.

Leading marijuana companies such as Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) are likely to follow the events in Washington, D.C., until a final decision on marijuana’s current status under the CSA is announced by the DEA.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

CannabisNewsBreaks — CBDWire to Expand Reach of Green Label Expo & Green Label Summit Las Vegas 2023

CBDWire, a specialized communications platform for the CBD sector and one of the 60+ brands within the InvestorBrandNetwork (“IBN”), today announced its collaboration with the Jotia Group to serve as the media sponsor and official newswire for the highly anticipated Green Label Expo Las Vegas and Green Label Summit. These distinctive, trailblazing cannabis trade shows allow exhibitors to provide live product demonstrations to attendees and are scheduled to take place at the Nuwu Dispensary in Las Vegas on Oct. 31 – Nov. 1, 2023. IBN and CBDWire will leverage a comprehensive range of solutions to amplify recognition for participating companies, breakthrough products and conference attendees, with a view to enhance visibility among investors, journalists, consumers, and the broader public. CBDWire will further expand article reach via syndication across 5,000+ outlets and feature the conference on dedicated event pages. “We are very pleased to be working with IBN and CBDWire towards improving outreach for the Summit and Expo in October,” said JR Richard, event director of the Green Label Series. “With specific expertise in the CBD space, CBDWire will elevate the status of the expo and boost our messaging while generating interest beyond traditional target markets through the latest social media strategies. We look forward to continuing this collaboration in the long run.”

To view the full press release, visit https://cnw.fm/EsltE

About CBDWire

CBDWire (“CBDW”) is a multilayered financial news and publishing company leveraging an innovative, CBD-focused approach to social media management, news distribution and press release enhancement. Backed by a proven team of writers and content creators, CBDW aims to effectively introduce public and private companies working in the CBD space to prospective investors, consumers and industry news outlets. The newswire service’s dissemination network currently spans over 5,000 downstream distribution points, allowing companies to cut through the noise and reach targeted audiences with carefully crafted messages.

About CannabisNewsWire

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com